SHARPE
Reported results
- Total revenues were $357.8 million for the third quarter of 2026, compared to $211.0 million for the third quarter of 2025.
- Total net product revenues were $275.9 million for the third quarter of 2026, compared to $131.0 million for the third quarter of 2025.
- GAAP R&D expenses were $105.4 million for the third quarter of 2026, compared to $100.2 million for the third quarter of 2025.
- Non-GAAP R&D expenses were $94.9 million for the third quarter of 2026, excluding $10.5 million in non-cash, stock-based compensation expense.
- GAAP SG&A expenses were $80.1 million for the third quarter of 2026, compared to $84.0 million for the third quarter of 2025.
- Net loss was $51.7 million for the third quarter of 2026, compared to net income of $15.9 million for the third quarter of 2025.
Guidance
- Full-year 2026 expected total revenue is $1.29 to $1.32 billion.
- Full-year 2026 total product revenue guidance is $960 to $990 million.
- Full-year 2026 GAAP R&D and SG&A expense guidance is $775 to $815 million.
- Full-year 2026 non-GAAP R&D and SG&A expense guidance is $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million.
Price and volatility reaction
The stock moved -7.0% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 64.46 | 2026-10-29 |
| Close after release | 59.97 | 2026-10-30 |
| Realised move | -7.0% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.